The objectives of these analyses were to (1) develop a population pharmacokinetic/pharmacodynamic model for a novel COX-2 inhibitor (CS-706) using data from primarily Caucasian subjects, (2) predict responses in subpopulations of interest (including Japanese subjects), and (3) correlate pharmacodynamic parameters to safety outcomes. The model was developed using data from 130 healthy adults following single or multiple doses of CS-706.
March 1, 2007
Author(s): Shashank Rohatagi, Helen Kastrissios, Christine Yuying Gao, Nancy Zhang, J. Xu, James Moberly, Russell Wada, Kazutaka Yoshihara, Mao Takahashi, Kenneth Truitt, Daniel Salazar
Year: March 1, 2007